Inactive Instrument

Other languages GENB AS Other OTC

Equities

US3723032062

Real-time Estimate Cboe BZX Other stock markets 07:53:12 2024-07-12 am EDT			5-day change	1st Jan Change
26.78 ^USD	+47.63%		+0.50%	+10.11%

Jul. 10	Markets Powered by Alternating Current
Jul. 08	Myricx Pharma Ltd announced that it has received £90 million in funding from a group of investors	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AVIS D'ANALYSTES DU JOUR : Axa, Dassault Systèmes, ArcelorMittal, Worldline, Safran, Amundi...	Jul. 10
Les marchés branchés sur courant alternatif	Jul. 10
Borsa di Italia: Mercati collegati alla corrente alternata	Jul. 10
OPINIONES DE LOS ANALISTAS DEL DÍA : Acerinox, Aena, Amadeus, Sabadell, Santander, Bankinter, Caixabank, Axa, ArcelorMittal, Safran, Flatexdegiro, Amundi...	Jul. 10
Bolsa de Madrid: Mercados conectados a la corriente alterna	Jul. 10
Ambu A/S: Un líder innovador en equipos médicos de un solo uso	Jul. 02
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	Jun. 28
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	Jun. 28
En Direct des Marchés : Renault, L'Oréal, Schneider Electric, Atos, Nokia, Meta Platforms...	Jun. 28
Vous reprendrez bien un peu d'inflation ?	Jun. 28
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	Jun. 28
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	Jun. 28
Bolsa de Madrid: ¿Le apetece un poco más de inflación?	Jun. 28
Genmab Closes DKK3.5 Billion Share Buyback Early	Jun. 28
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	Jun. 27
Genmab Wins US Approval for Follicular Lymphoma Treatment	Jun. 27
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	Jun. 26
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	Jun. 26
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	Jun. 03
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	Jun. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT